For CeD, this aspect was particularly significant because previously the causative antigen, gluten, could only be administered to the gut, which made it impossible to distinguish direct topical immunotoxic effects from those mediated by activated gluten-specific CD4+ T cells. The gene discussed is CD4; the disease is cranioectodermal dysplasia.